Printer Friendly

IMMUNOMEDICS REPORTS CLINICAL RESULTS WITH GERM CELL CANCER DETECTION AGENT

 TORONTO, June 11 /PRNewswire/ -- At the 40th Annual Meeting of The Society of Nuclear Medicine in Toronto, Immunomedics, Inc. (NASDAQ: IMMU), Morris Plains, N.J., announced favorable clinical results with ImmuRAID(TM)-AFP, its monoclonal antibody-based imaging agent to detect germ cell cancers. In a study, the results of which were discussed by Dr. Donald A. Podoloff, professor of Radiology & Nuclear Medicine, M.D. at the Anderson Cancer Center in Houston, Texas, ImmuRAID-AFP was 90 percent accurate in detecting germ cell tumors in 31 patients with known cancers. Results with ImmuRAID-AFP were correlated to computed tomography (CT) and/or magnetic resonance imaging (MRI) scans and pathology.
 According to Dr. Podoloff, "Although relatively uncommon in the total population, germ cell cancers represent one of the most common malignancies in men from the ages of 15 to 35. Because this is a potentially curable disease, the ability to precisely detect sites of recurrence is very important in patient management. In this study of patients with known germ cell tumors, ImmuRAID-AFP was useful in the differentiation of active tumors from post-treatment changes." He added that, "We have seen no adverse reactions to the product; in particular, there has been no development of human antimouse antibody (HAMA) responses."
 ImmuRAID-AFP, currently in Phase I/II studies, holds Orphan Drug Status from the U.S. Food and Drug Administration. The product consists of an antibody fragment labeled with the radioisotope technetium-99m. Upon injection into the patient, the radiolabeled fragment seeks out and attaches to AFP (alpha-fetoprotein), a marker protein for liver and germ cell tumors of the testicles and ovaries. A standard nuclear medicine camera is used to locate the resulting radioisotope concentrations within the body, pinpointing the location of tumors.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases. The company currently has two therapeutics and five imaging products in human clinical trials. In addition, the company's colorectal cancer imaging agent, ImmuRAID(TM)-CEA, is under review for marketing approval by the U.S. Food and Drug Administration, as well as by regulatory agencies in Europe and Canada.
 -0- 6/11/93
 /CONTACT: Debra Wasser, director - corporate communications of Immunomedics, Inc., 201-605-1330 ext. 113/
 (IMMU)


CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU:

LD-MG -- NY002 -- 0944 06/11/93 08:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 11, 1993
Words:424
Previous Article:THERMO VOLTEK SIGNS LETTER OF INTENT TO ACQUIRE COMTEST INSTRUMENTATION
Next Article:ENGLISH CHINA CLAYS ANNOUNCES AGREEMENT TO ACQUIRE MERCK'S SPECIALTY CHEMICALS BUSINESS
Topics:


Related Articles
IMMUNOMEDICS REPORTS NEW CLINICAL RESULTS OF INFECTIOUS DISEASE IMAGING AGENT
IMMUNOMEDICS REPORTS FIRST CLINICAL RESULTS OF LYMPHOMA IMAGING AGENT
GERMAN STUDY SHOWS PROMISING RESULTS FOR IMMUNOMEDICS' INFECTIOUS DISEASE IMAGING AGENT
IMMUNOMEDICS' COLORECTAL CANCER DETECTION AGENT ACCLAIMED AT SURGICAL CONGRESS: FINDINGS SHOW ACCURACY OF OVER 90 PERCENT
IMMUNOMEDICS ANNOUNCES THIRD QUARTER 1993 FINANCIAL RESULTS IN LINE WITH COMPANY EXPECTATIONS
IMMUNOMEDICS REPORTS ON LYMPHOMA IMAGING AND THERAPY PROGRESS AT CANCER CONFERENCE
Immunomedics Reports Clinical Advances With Three Diagnostic Imaging Products; Data Presented at 44th Society of Nuclear Medicine Annual Meeting
Immunomedics and Beckman Coulter Form Joint Venture to Develop Cancer Therapeutics
Immunomedics Reports Potential New Cancer Immunotherapy.
Immunomedics Expands Cancer Therapy Focus in Research Agreement With National Cancer Institute.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters